205 related articles for article (PubMed ID: 35090068)
21. Efficacy of the GMALL-B-ALL/NHL2002 protocol in Burkitt leukemia/lymphoma and aggressive non-Hodgkin-lymphomas with or without CNS involvement.
Sakarou M; Eisele L; Dührsen U; Hüttmann A
Eur J Haematol; 2019 Mar; 102(3):241-250. PubMed ID: 30471148
[TBL] [Abstract][Full Text] [Related]
22. Comparative immunohistochemical analysis of pediatric Burkitt lymphoma and diffuse large B-cell lymphoma.
Frost M; Newell J; Lones MA; Tripp SR; Cairo MS; Perkins SL
Am J Clin Pathol; 2004 Mar; 121(3):384-92. PubMed ID: 15023043
[TBL] [Abstract][Full Text] [Related]
23. Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas.
Pillai RK; Sathanoori M; Van Oss SB; Swerdlow SH
Am J Surg Pathol; 2013 Mar; 37(3):323-32. PubMed ID: 23348205
[TBL] [Abstract][Full Text] [Related]
24. Aggressive B-cell lymphomas: frequency, immunophenotype, and genetics in a reference laboratory population.
Naeini YB; Wu A; O'Malley DP
Ann Diagn Pathol; 2016 Dec; 25():7-14. PubMed ID: 27806850
[TBL] [Abstract][Full Text] [Related]
25. Diffuse large B-cell lymphomas and burkitt lymphoma.
de Leval L; Hasserjian RP
Hematol Oncol Clin North Am; 2009 Aug; 23(4):791-827. PubMed ID: 19577170
[TBL] [Abstract][Full Text] [Related]
26. Exhaustion of tumour-infiltrating T-cell receptor repertoire diversity is an age-dependent indicator of immunological fitness independently predictive of clinical outcome in Burkitt lymphoma.
Rieken J; Bernard V; Witte HM; Peter W; Merz H; Olschewski V; Hertel L; Lehnert H; Biersack H; von Bubnoff N; Feller AC; Gebauer N
Br J Haematol; 2021 Apr; 193(1):138-149. PubMed ID: 32945554
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of S1PR1, pSTAT3, S1PR2, FOXP1 Expression in Aggressive, Mature B Cell Lymphomas.
Al-Kawaaz M; Sanchez T; Kluk MJ
J Hematop; 2019 Jun; 12(2):57-65. PubMed ID: 31404445
[TBL] [Abstract][Full Text] [Related]
28. The Burkitt-like lymphomas: a Southwest Oncology Group study delineating phenotypic, genotypic, and clinical features.
Braziel RM; Arber DA; Slovak ML; Gulley ML; Spier C; Kjeldsberg C; Unger J; Miller TP; Tubbs R; Leith C; Fisher RI; Grogan TM
Blood; 2001 Jun; 97(12):3713-20. PubMed ID: 11389007
[TBL] [Abstract][Full Text] [Related]
29. Diagnosis of 'double hit' diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHC.
Swerdlow SH
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):90-9. PubMed ID: 25696840
[TBL] [Abstract][Full Text] [Related]
30. High-grade B-cell lymphoma (HGBL)-NOS is clinicopathologically and genetically more similar to DLBCL/HGBL-DH than DLBCL.
Li S; Qiu L; Xu J; Lin P; Ok CY; Tang G; McDonnell TJ; James You M; Khanlari M; Miranda RN; Medeiros LJ
Leukemia; 2023 Feb; 37(2):422-432. PubMed ID: 36513804
[TBL] [Abstract][Full Text] [Related]
31. Current Treatment of Burkitt Lymphoma and High-Grade B-Cell Lymphomas.
Johnson PC; Abramson JS
Oncology (Williston Park); 2022 Aug; 36(8):499-505. PubMed ID: 36001789
[TBL] [Abstract][Full Text] [Related]
32. Case report: Mutation evolution in a patient with TdT positive high grade B cell lymphoma with MYC and BCL2 rearrangements following the treatment of concurrent follicular lymphoma and diffuse large B-cell lymphoma.
Zhang F; Chen Y; Cui Q; Ge Y; Liu Y
Discov Oncol; 2024 Apr; 15(1):129. PubMed ID: 38662249
[TBL] [Abstract][Full Text] [Related]
33. [Aggressive B-cell lymphomas of gastrointestinal tract: a clinicopathologic analysis of 54 cases].
Zhou J; Xia C; Shen Q; Yin H; Zhang X; Shi Q; Zhou X; Ma J
Zhonghua Bing Li Xue Za Zhi; 2014 Jan; 43(1):8-14. PubMed ID: 24713242
[TBL] [Abstract][Full Text] [Related]
34. High-grade mature B-cell lymphoma with Burkitt-like morphology: results of a clinicopathological study of 72 Japanese patients.
Nomura Y; Karube K; Suzuki R; Ying G; Takeshita M; Hirose S; Nakamura S; Yoshino T; Kikuchi M; Ohshima K
Cancer Sci; 2008 Feb; 99(2):246-52. PubMed ID: 18271922
[TBL] [Abstract][Full Text] [Related]
35. Aggressive non-Hodgkin lymphoma in the pediatric and young adult population; diagnostic and molecular pearls of wisdom.
Singh A; Obiorah IE
Semin Diagn Pathol; 2023 Nov; 40(6):392-400. PubMed ID: 37400280
[TBL] [Abstract][Full Text] [Related]
36. Identification of ADGRE5 as discriminating MYC target between Burkitt lymphoma and diffuse large B-cell lymphoma.
Kleo K; Dimitrova L; Oker E; Tomaszewski N; Berg E; Taruttis F; Engelmann JC; Schwarzfischer P; Reinders J; Spang R; Gronwald W; Oefner PJ; Hummel M
BMC Cancer; 2019 Apr; 19(1):322. PubMed ID: 30953469
[TBL] [Abstract][Full Text] [Related]
37. Burkitt lymphoma versus diffuse large B-cell lymphoma: a practical approach.
Bellan C; Stefano L; Giulia de F; Rogena EA; Lorenzo L
Hematol Oncol; 2009 Dec; 27(4):182-5. PubMed ID: 19670467
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic challenges in a case of B cell lymphoma unclassifiable with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma.
So CC; Yung KH; Chu ML; Wan TS
Int J Hematol; 2013 Oct; 98(4):478-82. PubMed ID: 23959583
[TBL] [Abstract][Full Text] [Related]
39. Aggressive B-cell lymphoma cases with 11q aberration patterns indicate a spectrum beyond Burkitt-like lymphoma.
Gebauer N; Witte HM; Merz H; Oschlies I; Klapper W; Caliebe A; Tharun L; Spielmann M; von Bubnoff N; Feller AC; Murga Penas EM
Blood Adv; 2021 Dec; 5(23):5220-5225. PubMed ID: 34500469
[TBL] [Abstract][Full Text] [Related]
40. The importance of CD39, CD43, CD81, and CD95 expression for differentiating B cell lymphoma by flow cytometry.
Cardoso CC; Auat M; Santos-Pirath IM; Rudolf-Oliveira RCM; da Silva JP; Lange BG; Siegel D; de Moraes ACR; Del Moral JAG; Santos-Silva MC
Cytometry B Clin Cytom; 2018 May; 94(3):451-458. PubMed ID: 28509416
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
